In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Could a diabetes and weight loss drug benefit the brain? Here’s what scientists are learning. By Dana G. Smith and Dani Blum Over a decade ago, a smattering of studies suggested that early ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous Brenton Blanchet is a writer-reporter at PEOPLE. He has been working at PEOPLE ...

Zepbound). A survey of neuro-ophthalmologists turned up seven cases of nonarteritic ischemic anterior optic neuropathy (NAION), one case of bilateral papillitis, and one case of paracentral acute ...

Rates for money-market mutual funds are also moving lower, but they're still giving many banks a run for their money. Money-market funds are not bank accounts, but super-safe investment ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

The measure of price increases targeted by the Federal Reserve sped up in December, reflecting a stubborn spell of inflation that remains modestly higher than the central bank's target. The ...